The Prevalence of Mycobacterium Tuberculosis Infection Among Cancer Patients Receiving Chemotherapy in a Tertiary Care Center

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2023 Jan 5

PMID 36600835

Authors

Mona A Aldabbagh

Asma Abughasham

Ghaday Alansari

Suaad Bougis

Ealaf Melibari

Nada Alhatmi

Muhammad A Khan

Wasil Jastaniah

Affiliations

Soon will be listed here.

Abstract

Objective: To estimate the prevalence of tuberculosis (TB) infection among patients receiving cancer chemotherapy and to identify risk factors for latent TB reactivation.

Methods: A cross-sectional study was conducted at a tertiary care center in Jeddah, Saudi Arabia. Patients were surveyed for TB risk factors, their records were reviewed for previous TB infection or disease, and blood samples were collected for interferon-gamma release assays (IGRAs).

Results: A total of 203 patients were included. One hundred and twenty-five were females (62%). Median age was 52 years, and mean age was significantly higher in positive IGRA patients compared to negative IGRA (57.32 vs. 47.27; = 0.009). Twenty-five patients (12.3%) had evidence of TB infection, 16 (68%) among them had a latent TB infection, while the rest received treatment for an active TB disease. The rate of active disease among cancer patients was 8 (3.9%). Additionally, 92% (23) of those with positive IGRA had solid cancers ( = 0.007), and all active TB cases occurred in this group of solid cancers.

Conclusion: TB prevalence was higher in chemotherapy patients compared to the general Saudi population. Patients with solid tumors and older age had a greater risk of developing the infection, signifying the importance of preventing TB and malignancy coexistence by initiating screening policies in cancer patients.

Citing Articles

Investigation of the prevalence of latent tuberculosis in cancer patients compared to non-cancer patients: a case-control study.

Mortezazadeh M, Karimi M, Esfandbod M, Mofidi A, Hemmati N, Kashani M Oncol Rev. 2024; 18:1445678.

PMID: 39697587 PMC: 11652964. DOI: 10.3389/or.2024.1445678.

Open questions between immune checkpoint inhibitors and tuberculosis incidence.

Wen Y, Kang J J Thorac Dis. 2024; 16(8):5484-5486.

PMID: 39268138 PMC: 11388239. DOI: 10.21037/jtd-24-890.

The controversy of immune checkpoint inhibition and risk of mycobacterial infections: the need for further studies and continued discussions on this puzzling issue.

Chan E J Thorac Dis. 2024; 16(8):5487-5489.

PMID: 39268105 PMC: 11388230. DOI: 10.21037/jtd-24-1005.

The Prevalence of Mycobacterium Tuberculosis Infection in Saudi Arabia: A Systematic Review and Meta-analysis.

Said B, Mohamed A, Eltyeb E, Eltayeb R, Abdalghani N, Siddig B J Epidemiol Glob Health. 2024; 14(3):658-676.

PMID: 39046668 PMC: 11442870. DOI: 10.1007/s44197-024-00274-w.

Advancements in Artificial Intelligence for the Diagnosis of Multidrug Resistance and Extensively Drug-Resistant Tuberculosis: A Comprehensive Review.

K S, Parivakkam Mani A, S G, Yadav S Cureus. 2024; 16(5):e60280.

PMID: 38872656 PMC: 11173349. DOI: 10.7759/cureus.60280.

References

Al-Orainey I, Alhedaithy M, Alanazi A, Barry M, Almajid F . Tuberculosis incidence trends in Saudi Arabia over 20 years: 1991-2010. Ann Thorac Med. 2013; 8(3):148-52. PMC: 3731856. DOI: 10.4103/1817-1737.114303. View

Balkhy H, El Beltagy K, El-Saed A, Aljasir B, Althaqafi A, Alothman A . Prevalence of Latent Mycobacterium Tuberculosis Infection (LTBI) in Saudi Arabia; Population based survey. Int J Infect Dis. 2017; 60:11-16. DOI: 10.1016/j.ijid.2017.03.024. View

Ku C, Dodd P . Forecasting the impact of population ageing on tuberculosis incidence. PLoS One. 2019; 14(9):e0222937. PMC: 6759178. DOI: 10.1371/journal.pone.0222937. View

Childs B, Durik M, Baker D, van Deursen J . Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med. 2015; 21(12):1424-35. PMC: 4748967. DOI: 10.1038/nm.4000. View

Hofmeyr A, Lau W, Slavin M . Mycobacterium tuberculosis infection in patients with cancer, the role of 18-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring treatment response. Tuberculosis (Edinb). 2007; 87(5):459-63. DOI: 10.1016/j.tube.2007.05.013. View

Nair R, Prabhash K, Sengar M, Bakshi A, Gujral S, Gupta S . The effect of short-term intensive chemotherapy on reactivation of tuberculosis. Ann Oncol. 2007; 18(7):1243-5. DOI: 10.1093/annonc/mdm107. View

Bae S, Kim Y, Kim M, Kim J, Yun S, Jung J . Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study. J Immunother Cancer. 2021; 9(9). PMC: 8442094. DOI: 10.1136/jitc-2021-002960. View

Kim H, Hwang S, Ro Y, Jeon C, Ha D, Park S . Solid-organ malignancy as a risk factor for tuberculosis. Respirology. 2008; 13(3):413-9. DOI: 10.1111/j.1440-1843.2008.01282.x. View

Anastasopoulou A, Ziogas D, Samarkos M, Kirkwood J, Gogas H . Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer. 2019; 7(1):239. PMC: 6727332. DOI: 10.1186/s40425-019-0717-7. View

10.

Nanthanangkul S, Promthet S, Suwanrungruang K, Santong C, Vatanasapt P . Incidence of and Risk Factors for Tuberculosis among Cancer Patients in Endemic Area: A Regional Cohort Study. Asian Pac J Cancer Prev. 2020; 21(9):2715-2721. PMC: 7779434. DOI: 10.31557/APJCP.2020.21.9.2715. View

11.

Jacobs R, Gu P, Chachoua A . Reactivation of pulmonary tuberculosis during cancer treatment. Int J Mycobacteriol. 2016; 4(4):337-40. DOI: 10.1016/j.ijmyco.2015.05.015. View

12.

Cheng M, Abou Chakra C, Yansouni C, Cnossen S, Shrier I, Menzies D . Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2016; 64(5):635-644. DOI: 10.1093/cid/ciw838. View

13.

Pai M, Menzies D . The new IGRA and the old TST: making good use of disagreement. Am J Respir Crit Care Med. 2007; 175(6):529-31. DOI: 10.1164/rccm.200701-024ED. View

14.

Lopez-Otin C, Blasco M, Partridge L, Serrano M, Kroemer G . The hallmarks of aging. Cell. 2013; 153(6):1194-217. PMC: 3836174. DOI: 10.1016/j.cell.2013.05.039. View

15.

Fujita T, Endo M, Gu Y, Sato T, Ohmagari N . Mycobacterium tuberculosis infection in cancer patients at a tertiary care cancer center in Japan. J Infect Chemother. 2014; 20(3):213-6. DOI: 10.1016/j.jiac.2013.11.005. View

16.

Al-Orainey I . Tuberculosis infection during Hajj pilgrimage. The risk to pilgrims and their communities. Saudi Med J. 2013; 34(7):676-80. View

17.

Karakas Z, Agaoglu L, Taravari B, Saribeyoglu E, Somer A, Guler N . Pulmonary tuberculosis in children with Hodgkin's lymphoma. Hematol J. 2003; 4(1):78-81. DOI: 10.1038/sj.thj.6200219. View

18.

Khan B, Ahmed P, Ullah K, Hussain C, Hussain I, Raza S . Frequency of tuberculosis in haematological malignancies and stem cell transplant recipients. J Coll Physicians Surg Pak. 2005; 15(1):30-3. DOI: 01.2005/JCPSP.3033. View

19.

Stefan D, Kruis A, Schaaf H, Wessels G . Tuberculosis in oncology patients. Ann Trop Paediatr. 2008; 28(2):111-6. DOI: 10.1179/146532808X302125. View

20.

Mazurek G, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K . Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep. 2010; 59(RR-5):1-25. View